CG400549

DRUG2 trials

Sponsors

CrystalGenomics, Inc.

Conditions

HealthySkin Infection

Phase 1

CG400549 Single Ascending Dose Study

CompletedNCT01085578

CrystalGenomics, Inc.Healthy

Start: 2009-10-31End: 2009-12-31Updated: 2022-05-20

Phase 2

Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus

CompletedNCT01593761

CrystalGenomics, Inc.Skin Infection

Start: 2012-06-30End: 2012-10-31Updated: 2022-09-10